Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
Brian G. Feagan(Western University), Rupert W. Leong(The University of Sydney), М. Ф. Осипенко(Novosibirsk State Medical University), Liudmyla Nykodymivna Prystupa, Olga Vasilevskaya, Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Shiraz Farooq, Anatoly Pershko, Juan S. Lasa, William J. Sandborn(University of San Diego), Emiliano Tron, Jarosław Kierkuś(Children's Memorial Health Institute), Mykola Stanislavchuk(National Pirogov Memorial Medical University, Vinnytsya), Carlos Fernando de Magalhães Francesconi, D Kleczkowski, Julián Panés(Hospital Clínic de Barcelona), Grażyna Rydzewska(Ministry of Interior and Administration), Tkachev Av(Rostov State Medical University), Abel Novillo, Olena Datsenko, Nataliia Tsarynna, Jakob Begun, Marek Woynarowski(Yale University), Olha Ivanishyn, Oleksandr Golovchenko, Dilara Kalimullina, Maria de Lourdes de Abreu Ferrari, Elina Petrova, Leonid Bilіanskyi, В. И. Симаненков(North-Western State Medical University named after I.I. Mechnikov), Finlay Macrae(The Royal Melbourne Hospital), Elena Bunkova, William Holderman(University of California San Diego), Jarosław Leszczyszyn, Oleksii Gridnyev, Andrii Yurkiv, A. A. Obrezan, Halyna Afanasieva, Pedro López(Universidade Federal do Rio Grande do Sul), Jie Shao(Janssen (United States)), О. Аbrahamovych, Dmitry Platonov, Marion Vetter(Janssen (United States)), Felix Tiongco, Shihong Sheng(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Robert Petryka, Matthew Germinaro(Johnson & Johnson (United States)), Ihor Hospodarsky, О. Б. Щукина(City Clinical Hospital No 31)
Cited by 235
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k